Steinar Aamdal
University of Oslo · 196 works · 8,727 citations · h-index 44
Top works
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
- Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results
- Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up
- 9304 Identification of tumor biopsy markers as potential predictors of ipilimumab clinical activity in patients with advanced melanoma
- Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment.
- Estrogen receptors and long-term prognosis in breast cancer
- Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression.
- Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report
- The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up
- Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC early clinical trials group
- Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas.
- A new experimental metastasis model in athymic nude mice, the human malignant melanoma lox
- Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon
- Defining the critical hurdles in cancer immunotherapy
- Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease
- Hypofractionated Palliative Radiotherapy (17 Gy per two fractions) in Advanced Non–Small-Cell Lung Carcinoma Is Comparable to Standard Fractionation for Symptom Control and Survival: A National Phase III Trial
- Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer